About AST

Transplant News

March, 2014

March 11, 2014
The Transplant Roundtable, a coalition of organ transplant patients, health professionals, and related organizations dedicated to preserving transplant patients' access to optimal care, recently provided comments to the Centers for Medicare and Medicaid Services (CMS) Medicare Program; Contract Year 2015 Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs (the "Proposed Rule"). The Proposed Rule would enable Part D sponsors to impose formulary restrictions on immunosuppressive drugs, resulting in substantial risk of organ rejection,... Read More...
March 10, 2014
Earlier today, the Obama Administration informed top congressional leaders that it will not finalize any of the changes it had proposed to the Six Protected Classes Policy in the Jan. 10 regulation... including the proposed removal of transplant immuno drugs from the protected class category. They note the considerable pushback received on this and some other aspects of the rule during the comment period. It was also pointed out, that the issues may be revisited in future years. As you know, AST submitted official comments opposing the rule to CMS. The AST was mentioned by name at the recent... Read More...
March 06, 2014
A video podcast developed by OPTN and UNOS entitled "The New Kidney Allocation System: What Referring Physicians Need to Know” is now available on the OPTN and Transplant Pro websites.  View the video on the OPTN website View the video on the UNIOS Transplant Pro website Download the slides here to follow along with the... Read More...
March 03, 2014
UNOS welcomes applications for a Chief Medical Officer (CMO), an executive-level position reporting to UNOS’ Chief Executive Officer. As a member of the UNOS senior staff, the CMO serves as an expert medical and clinical resource to other UNOS staff, committee members, the government, and the general public in the performance of OPTN contract requirements and other UNOS corporate initiatives. He or she will provide advice with respect to the medical and clinical aspects of OPTN operations, including participation in OPTN policy development, policy compliance, patient safety-related incident... Read More...

February, 2014

February 26, 2014
The American Society of Transplantation has serious concerns regarding the proposed rule to remove immunosuppressant medications for transplant rejection prophylaxis as a protected class under Medicare Parts C and D. To view the full statement please follow the link below: AST Statement Regarding Transplant community opposition to CMS proposal to remove Immunosuppressive medications from Medicare Part D Protected Class category  
February 26, 2014
The American Society of Transplantation (AST) Raises Concerns about Plans to Limit Medicare Drug Coverage; Calls Potential Changes “Life-Threatening” AST strongly opposes the CMS proposed rule to remove immunosuppressant medications as a protected class under Medicare Parts C and D WASHINGTON, DC – February 26, 2014 – The American Society of Transplantation (AST), representing the majority of professionals engaged in the field of organ transplantation, today expressed their concern about the Centers for Medicare & Medicaid Services (CMS) proposed rule to eliminate immunosuppressive... Read More...
February 21, 2014
Visit the AST Timely Topics in Transplantation webinar series webpage to view archived recordings of live webinars, including the "Complying with New UNOS Living Donor Care Policies" webinar which took place on February 18. Thank you to the presenters for their hard work in developing and presenting the informative content: Jennifer Milton BSN, CCTC, MBA of University Transplant Center and Rebecca Hays, MSW of University of Wisconsin Hospital and Clinics.
February 19, 2014
The AST recently submitted a letter to the Food and Drug Administration regarding draft guidance for (510(k)) submissions for nucleic acid-based HLA test kits. The AST endorsed comments from the American Society for Histocompatibility and Immunogenetics (ASHI) regarding this FDA draft guidance for industry Docket. View ASHI's comments here. View the AST's letter here.
February 07, 2014
Registration and housing is now open for the 2014 World Transplant Congress (WTC)! Register now and book your housing for the World Transplant Congress (WTC) in San Francisco, CA July 26-31, 2014.  Please make sure that your membership is current before registering. You must be a member in good standing by April 1, 2014.

Pages